Aligos Therapeutics

About:

Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.

Website: https://www.aligos.com

Twitter/X: Aligos7

Top Investors: Wellington Management, Cormorant Asset Management, Deep Track Capital, Janus Henderson Investors, Novo Holdings

Description:

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.